NLRP3-dependent pyroptosis is required for HIV-1 gp120-induced neuropathology

The human immunodeficiency virus-1 (HIV-1) envelope protein gp120 is the major contributor to the pathogenesis of HIV-associated neurocognitive disorder (HAND). Neuroinflammation plays a pivotal role in gp120-induced neuropathology, but how gp120 triggers neuroinflammatory processes and subsequent n...

Full description

Saved in:
Bibliographic Details
Published inCellular & molecular immunology Vol. 17; no. 3; pp. 283 - 299
Main Authors He, Xiaolong, Yang, Weijun, Zeng, Zhijie, Wei, Yi, Gao, Jie, Zhang, Bao, Li, Li, Liu, Liqun, Wan, Yu, Zeng, Qing, Gong, Zelong, Liu, Liting, Zhang, Hanyun, Li, Yubin, Yang, Shaojie, Hu, Tongtong, Wu, Lixian, Masliah, Eliezer, Huang, Shenghe, Cao, Hong
Format Journal Article
LanguageEnglish
Published London Nature Publishing Group UK 01.03.2020
Nature Publishing Group
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:The human immunodeficiency virus-1 (HIV-1) envelope protein gp120 is the major contributor to the pathogenesis of HIV-associated neurocognitive disorder (HAND). Neuroinflammation plays a pivotal role in gp120-induced neuropathology, but how gp120 triggers neuroinflammatory processes and subsequent neuronal death remains unknown. Here, we provide evidence that NLRP3 is required for gp120-induced neuroinflammation and neuropathy. Our results showed that gp120-induced NLRP3-dependent pyroptosis and IL-1β production in microglia. Inhibition of microglial NLRP3 inflammasome activation alleviated gp120-mediated neuroinflammatory factor release and neuronal injury. Importantly, we showed that chronic administration of MCC950, a novel selective NLRP3 inhibitor, to gp120 transgenic mice not only attenuated neuroinflammation and neuronal death but also promoted neuronal regeneration and restored the impaired neurocognitive function. In conclusion, our data revealed that the NLRP3 inflammasome is important for gp120-induced neuroinflammation and neuropathology and suggest that NLRP3 is a potential novel target for the treatment of HAND.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ISSN:1672-7681
2042-0226
2042-0226
DOI:10.1038/s41423-019-0260-y